INTRODUCTION
resuppression, viremia
VIREMIA
The World Health OrganizationIn these settings, HIV services are predominantly provided in primary care, where delays in receiving VL results from centralized laboratoriesNone of these trials focused on point-of-care testing among people with viremia, who may benefit the most from quicker access to VL results. We plan a future efficacy trial of a diagnostic intervention to improve resuppression among people with viremia and require further data to aid design of this trial. First, the global rollout of dolutegravir, which has a higher genetic barrier to resistance,We therefore aimed to conduct a feasibility study of a randomized trial of point-of-care VL testing to improve management viremia in the context of the dolutegravir-based ART rollout in South Africa.